Loading clinical trials...
Loading clinical trials...
A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Conditions
Interventions
INC280
Locations
47
United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
University of Chicago SC
Chicago, Illinois, United States
Karmanos Cancer Institute Wayne St Karmanos
Detroit, Michigan, United States
Sarah Cannon Research Institute Dept of Onc
Nashville, Tennessee, United States
University of Texas/MD Anderson Cancer Center Dept of Onc
Houston, Texas, United States
Novartis Investigative Site
Westmead, New South Wales, Australia
Start Date
February 29, 2012
Primary Completion Date
July 4, 2017
Completion Date
July 4, 2017
Last Updated
December 19, 2020
NCT04570423
NCT07489378
NCT07181681
NCT07204340
NCT07360314
NCT07539285
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions